Cardiac rehabilitation
BehavioralParticipation in a 12-week cardiac rehabilitation program
NCT Number: NCT06247774
The goal of this clinical trial is to learn about the molecular pathways associated with the benefit of a regular exercise program in patients with high blood pressure and who don't already participate in regular exercise.
The main question it aims to answer is to identify protein signatures associated with the benefits of a cardiac rehabilitation exercise program.
The trial will enroll 42 participants, who will be randomized to a 12 week cardiac rehabilitation exercise program versus control arm and asked to participate in the following at the beginning and end of study:
* Cardiopulmonary exercise test (CPET) * Echocardiogram * Physical function test * 6-minute walk test * Hand grip strength * Quality of life questionnaire * Blood draws
Researchers will compare results between those who do and don't participate in the exercise program.
Trial opening soon.
Get Notified65 year and older
All sexes
Interventional
Not applicable
Lifestyle modification with physical activity (PA) appears to be protective of several age-related cardiovascular (CV) outcomes, including heart failure (HF), in a dose-dependent manner. While many studies with exercise training have demonstrated improvement in quality of life and cardiorespiratory fitness, findings have not been consistent with regards to the potential for exercise to preserve or even improve cardiac function in adults with HF. There remains incomplete understanding of the molecular pathways by which PA mitigates HF risk. Furthermore, exercise studies often exclude older adults, who are disproportionately affected by HF, though our preliminary data suggest the protective effects of PA extend to late-life. Older adults are at particularly heightened risk for HF with preserved ejection fraction (HFpEF), which is characterized by impaired left ventricular (LV) diastolic function and impaired systolic deformation despite preserved LV ejection fraction (LVEF). Unlike with HF with reduced ejection fraction (HFrEF), effective pharmacologic therapies or interventions to improve cardiac function among individuals with preserved LVEF are limited. Thus, there is a critical need to define the cardiovascular mechanisms by which PA impacts HF risk in older adults that may enable the identification of novel therapeutic targets to prevent HF and HFpEF in particular.
As proteins orchestrate and carry out cellular functions in health and in diseases, one method of characterizing changes in CV function is to investigate cell signaling by studying the circulating proteome. Proteomic approaches have previously been used to identify pathways relevant to myocardial infarction and have also been used to investigate molecular pathways characterizing PA and CV disease. A recent study demonstrated upregulation of inflammation-related proteins in HFpEF patients (n=228) compared to controls, and their association with worse indices of cardiac function. Specific proteomic patterns have also been associated with aerobic exercise, with 2 proteomic modules that were specifically preserved with aging in habitual exercisers. Data from Swedish cohorts has also shown an association of leisure-time PA with 28 CV-specific proteins involved in atherosclerotic processes. Serial multi-omic measures (including proteomics) have been used to demonstrate marked intra-individual changes in circulating proteins with acute exercise. More recently, high-throughput proteomic profiling has been successfully employed in younger adults to identify baseline protein levels associated with change in cardiorespiratory fitness following an exercise intervention. However, to-date, limited data exist regarding intervention-related changes in the proteome in older adults at risk for HF and the extent to which these changes correlate with changes in cardiorespiratory fitness.
Supervised exercise-training with cardiac rehabilitation (CR) has been well established as an effective method to improve maximal oxygen consumption (VO2 max), a measure of cardiorespiratory fitness. Improvement in VO2 max has also been demonstrated with exercise training in sedentary older adults over 65 years of age.
The objective of this proposal is to identify protein signatures characterizing the known benefits of a structured CR program on VO2 max. Our working hypotheses is that proteomic approaches will identify novel biomarkers that uniquely characterize molecular pathways associated with exercise training and CR-related changes in proteins will correlate with changes in VO2 max. Successful completion of this aim will identify possible novel protein signatures underlying the protective biological pathways mediated by a structured CR program that may be used as preliminary data for future grant proposals.
Aim: Identify molecular pathways underlying the beneficial effect of a structured PA intervention on functional capacity with the use of plasma proteomics in older sedentary adults at high risk of HF. (BWH-based cohort). Hypotheses: (1) Randomization to participation in a cardiac rehabilitation (CR) program will result in improvement in circulating levels of 4 plasma proteins associated with change in VO2max, a measure of cardiorespiratory fitness, and with genetic evidence supporting a causal effect on HF and cardiac structure (ATF6, STC1, JAG1, PTK7). The investigators will randomize 42 sedentary adults at high risk of HF (stage B HF) to participation in a CR program and perform proteomic analysis, cardiopulmonary exercise testing, and echocardiography at baseline and 12 weeks.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participation in a 12-week cardiac rehabilitation program
Participants will receive regular phone calls in place of cardiac rehabilitation visits
Time frame: 12 weeks
Change in protein levels assessed by blood draws and measured by Somascan assay. ANCOVA analysis adjusting for baseline protein levels with intention to treat group assignment
Time frame: 12 weeks
Correlation of single protein changes associated with change in VO2 max
Time frame: 12 weeks
Correlation of single protein changes associated with change in LV global longitudinal strain
Time frame: 12 weeks
Correlation of single protein changes associated with change in LV diastolic function
Time frame: 12 weeks
Correlation of single protein changes associated with change in VE/VCO2
Time frame: 12 weeks
Correlation of single protein changes associated with change in Short Physical Performance Battery (SPPB)
Time frame: 12 weeks
Correlation of single protein changes associated with change in 6-minute walk test
Time frame: 12 weeks
Correlation of single protein changes associated with change in grip strength
Time frame: 12 weeks
Correlation of single protein changes associated with change in EQ-5D (QOL)
Time frame: 12 weeks
Correlation of single protein changes associated with change in step counts
Time frame: 12 weeks
Correlation of baseline proteins with change in VO2 max
Time frame: 12 weeks
Correlation of baseline proteins with change in LV global longitudinal strain
Time frame: 12 weeks
Correlation of baseline proteins with change in LV diastolic function
Time frame: 12 weeks
Correlation of baseline proteins with change in VE/VCO2
Time frame: 12 weeks
Correlation of baseline proteins with change in SPPB
Time frame: 12 weeks
Correlation of baseline proteins with change in 6-minute walk test
Time frame: 12 weeks
Correlation of baseline proteins with change in grip strength
Time frame: 12 weeks
Correlation of baseline proteins with change in EQ-5D (QOL)
Time frame: 12 weeks
Correlation of baseline proteins with change in step counts
Contact information is provided by the study sponsor or research team.
Brigham and Women's Hospital
Other
Reducing Heart Failure Risk in Late-Life With Physical Activity: Impact on Cardiac Structure and Function and Proteomic Signatures
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06759805
Adherence, Medication, Adherence, Treatment
Bergen, Norway
View Trial DetailsNCT06295848
Arthritis, Arthritis, Rheumatoid
Kayseri, Kocasinan, Turkey (Türkiye)
View Trial DetailsNCT07730879
Apnea, Cardiovascular Diseases
Braga, Portugal
View Trial DetailsNCT07719660
Blood Pressure Monitoring, Cardiovascular Diseases
Dresden, Saxony, Germany
View Trial Details